GlassScriptPhysician profile
Amos Anderson
NPI 1568473429
$5,515.66
in general payments reported to CMS, 2019-2025
38 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $281 · 2021: $1,318 · 2022: $1,420 · 2023: $972 · 2024: $325 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $812.57 | 2021-2024 | Interstim |
| Cook Medical LLC | $747.54 | 2019-2023 | Fiber Dust, Resonance |
| Boston Scientific Corporation | $732.79 | 2021-2022 | |
| Astellas Pharma US INC | $698.55 | 2019-2022 | |
| Pfizer INC. | $292.96 | 2019-2023 | |
| Abbvie INC. | $261.33 | 2019-2023 | Botox, Lupron Depot |
| Teleflex LLC | $214.02 | 2024-2025 | Barrigel |
| Bayer Healthcare Pharmaceuticals INC. | $208.51 | 2019-2023 | |
| Janssen Biotech, INC. | $146.89 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $138.96 | 2019-2023 | Aveed, Xiaflex |
| Blue Earth Diagnostics | $124.61 | 2019-2021 | |
| Myovant Sciences INC. | $117.88 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $113.92 | 2019-2022 | |
| Urogen Pharma, INC. | $89.94 | 2021-2023 | Jelmyto |
| Axonics, INC. | $70.00 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amos Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.